Aethlon Medical (AEMD) 10-Q 14 Nov 22 2022 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Sep. 30, 2022	Nov. 10, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2022
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--03-31
Entity File Number	001-37487
Entity Registrant Name	AETHLON MEDICAL, INC.
Entity Central Index Key	0000882291
Entity Tax Identification Number	13-3632859
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	11555 SORRENTO VALLEY ROAD
Entity Address, Address Line Two	SUITE 203
Entity Address, City or Town	SAN DIEGO
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92121
City Area Code	619
Local Phone Number	941-0360
Title of 12(b) Security	Common Stock
Trading Symbol	AEMD
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		22,946,232

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)	Sep. 30, 2022	Mar. 31, 2022
Current assets
Cash	$ 19,604,025	$ 17,072,419
Accounts receivable	114,849	127,965
Prepaid expenses and other current assets	784,638	956,623
Total current assets	20,503,512	18,157,007
Property and equipment, net	1,138,623	441,238
Right-of-use lease asset	1,282,328	696,698
Patents, net	1,925	2,200
Restricted cash	87,506	87,506
Deposits	33,305	33,305
Total assets	23,047,199	19,417,954
Current liabilities
Accounts payable	361,001	499,962
Due to related parties	177,527	155,742
Deferred revenue	574,245	344,547
Lease liability, current portion	247,144	126,905
Other current liabilities	741,529	696,893
Total current liabilities	2,101,446	1,824,049
Lease liability, less current portion	1,077,529	602,505
Total liabilities	3,178,975	2,426,554
Stockholders’ Equity
Common stock, par value $0.001 per share; 60,000,000 and 30,000,000 shares authorized as of September 30, 2022 and March 31, 2022, respectively; 22,946,232 and 15,419,163 shares issued and outstanding as of September 30, 2022 and March 31, 2022, respectively	22,948	15,421
Additional paid-in capital	156,887,555	147,446,868
Accumulated deficit	(137,042,279)	(130,329,181)
Total Aethlon Medical, Inc. stockholders’ equity before noncontrolling interests	19,868,224	17,133,108
Noncontrolling interests	0	(141,708)
Total stockholders’ equity	19,868,224	16,991,400
Total liabilities and stockholders’ equity	$ 23,047,199	$ 19,417,954

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2022	Mar. 31, 2021
Statement of Financial Position [Abstract]
Common stock par value (in dollars per share)	$ 0.001	$ 0.001
Common stock shares authorized	60,000,000	30,000,000
Common stock issued	22,946,232	15,419,163
Common stock outstanding	22,946,232	15,419,163

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
REVENUES
Government contract revenue	$ 0	$ 131,966	$ 0	$ 263,932
OPERATING EXPENSES
Professional fees	1,003,870	649,460	1,847,899	1,232,929
Payroll and related expenses	1,112,955	805,608	2,142,641	1,822,350
General and administrative	1,548,484	685,702	2,582,505	1,315,895
Total operating expenses	3,665,309	2,140,770	6,573,045	4,371,174
OPERATING LOSS	(3,665,309)	(2,008,804)	(6,573,045)	(4,107,242)
OTHER EXPENSE
Loss on dissolution of subsidiary	142,121	0	142,121	0
NET LOSS	(3,807,430)	(2,008,804)	(6,715,166)	(4,107,242)
LOSS ATTRIBUTABLE TO NONCONTROLLING INTERESTS	0	(825)	0	(1,960)
NET LOSS ATTRIBUTABLE TO AETHLON MEDICAL, INC.	$ (3,807,430)	$ (2,007,979)	$ (6,715,166)	$ (4,105,282)
BASIC LOSS PER SHARE	$ (0.18)	$ (0.13)	$ (0.37)	$ (0.29)
DILUTED LOSS PER SHARE	$ (0.18)	$ (0.13)	$ (0.37)	$ (0.29)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING – BASIC	20,744,999	15,386,486	18,130,177	14,114,639
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING – DILUTED	20,744,999	15,386,486	18,130,177	14,114,639

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDER'S EQUITY (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Noncontrolling Interest [Member]	Total
BALANCE - JUNE 30, 2021 at Mar. 31, 2021	$ 12,152	$ 129,331,542	$ (119,913,090)	$ (136,914)	$ 9,293,690
Beginning balance, shares at Mar. 31, 2021	12,150,597
Issuances of common stock for cash under at the market program	$ 626	4,947,159			4,947,785
Issuances of common stock for cash under at the market program, shares	626,000
Issuances of common stock for cash in registered direct financing	$ 1,381	11,657,663			11,659,044
Issuances of common stock for cash in registered direct financing, shares	1,380,555
Issuances of common stock for cash under warrant exercises	$ 531	820,407			820,938
Issuances of common stock for cash under warrant exercises, shares	531,167
Issuances of common stock for cash under stock option exercises	$ 11	28,314			28,325
Issuances of common stock for cash under stock option exercises, shares	11,562
Issuances of common stock under cashless warrant exercises	$ 676	(676)
Issuances of common stock under cashless warrant exercises, shares	675,554
Issuances of common stock upon vesting of restricted stock units	$ 11	(35,797)			(35,786)
Issuance of common stock upon vesting of restricted stock units, shares	10,932
Stock-based compensation expense		120,154			120,154
Net loss			(2,097,303)	(1,135)	(2,098,438)
BALANCE – SEPTEMBER 30, 2021 at Jun. 30, 2021	$ 15,388	146,868,766	(122,010,393)	(138,049)	24,735,712
Ending balance, shares at Jun. 30, 2021	15,386,367
Issuances of common stock upon vesting of restricted stock units	$ 11	(28,145)			(28,134)
Issuance of common stock upon vesting of restricted stock units, shares	10,932
Stock-based compensation expense		201,062			201,062
Net loss			(2,007,979)	(825)	(2,008,804)
BALANCE – SEPTEMBER 30, 2021 at Sep. 30, 2021	$ 15,399	147,041,683	(124,018,372)	(138,874)	22,899,836
Ending balance, shares at Sep. 30, 2021	15,397,299
BALANCE - JUNE 30, 2021 at Mar. 31, 2022	$ 15,421	147,446,868	(130,329,181)	(141,708)	16,991,400
Beginning balance, shares at Mar. 31, 2022	15,419,163
Issuances of common stock for cash under at the market program	$ 575	618,867			619,442
Issuances of common stock for cash under at the market program, shares	574,560
Stock-based compensation expense		215,437			215,437
Net loss			(2,905,668)	(413)	(2,906,081)
BALANCE – SEPTEMBER 30, 2021 at Jun. 30, 2022	$ 15,996	148,281,172	(133,234,849)	(142,121)	14,920,198
Ending balance, shares at Jun. 30, 2022	15,993,723
BALANCE - JUNE 30, 2021 at Mar. 31, 2022	$ 15,421	147,446,868	(130,329,181)	(141,708)	16,991,400
Beginning balance, shares at Mar. 31, 2022	15,419,163
BALANCE – SEPTEMBER 30, 2021 at Sep. 30, 2022	$ 22,948	156,887,555	(137,042,279)		19,868,224
Ending balance, shares at Sep. 30, 2022	22,946,232
BALANCE - JUNE 30, 2021 at Jun. 30, 2022	$ 15,996	148,281,172	(133,234,849)	(142,121)	14,920,198
Beginning balance, shares at Jun. 30, 2022	15,993,723
Issuances of common stock for cash under at the market program	$ 6,906	8,300,863			8,307,769
Issuances of common stock for cash under at the market program, shares	6,906,276
Issuances of common stock upon vesting of restricted stock units	$ 46	(8,019)			(7,973)
Issuance of common stock upon vesting of restricted stock units, shares	46,233
Stock-based compensation expense		313,539			313,539
Loss on dissolution of subsidiary				142,121	142,121
Net loss			(3,807,430)		(3,807,430)
BALANCE – SEPTEMBER 30, 2021 at Sep. 30, 2022	$ 22,948	$ 156,887,555	$ (137,042,279)		$ 19,868,224
Ending balance, shares at Sep. 30, 2022	22,946,232

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	6 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash flows used in operating activities:
Net loss	$ (6,715,166)	$ (4,107,242)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	83,224	80,690
Stock based compensation	528,975	321,216
Accretion of right-of-use lease asset	9,633	(2,180)
Loss of dissolution of subsidiary	142,121	0
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	173,856	98,772
Accounts receivable	13,116	17,116
Accounts payable and other current liabilities	(94,540)	(374,020)
Deferred revenue	229,698	0
Due to related parties	21,785	15,687
Net cash used in operating activities	(5,607,298)	(3,949,961)
Cash flows used in investing activities:
Purchases of property and equipment	(780,334)	(78,861)
Net cash used in investing activities	(780,334)	(78,861)
Cash flows provided by financing activities:
Proceeds from the issuance of common stock, net	8,927,211	17,456,092
Tax withholding payments or tax equivalent payments for net share settlement of restricted stock units and net stock option expense	(7,973)	(63,920)
Net cash provided by financing activities	8,919,238	17,392,172
Net increase in cash and restricted cash	2,531,606	13,363,350
Cash and restricted cash at beginning of period	17,159,925	9,908,301
Cash and restricted cash	19,691,531	23,271,651
Supplemental disclosures of non-cash investing and financing activities:
Issuance of common stock under cashless warrant exercises	0	676
Par value of shares issued for vested restricted stock units and net stock option exercise	46	22
Initial recognition of right-of-use lease asset and lease liability	625,471	0
Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets:
Cash and cash equivalents	19,604,025	23,224,925
Restricted cash	$ 87,506	$ 46,726

NATURE OF BUSINESS AND BASIS OF

NATURE OF BUSINESS AND BASIS OF PRESENTATION ORGANIZATION	6 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
NATURE OF BUSINESS AND BASIS OF PRESENTATION ORGANIZATION	1. NATURE OF BUSINESS AND BASIS OF PRESENTATION ORGANIZATION Aethlon Medical, Inc. (“Aethlon”, the “Company”, “we” or “us”) is a medical therapeutic company focused on developing products to diagnose and treat cancer and life threatening infectious diseases. The Aethlon Hemopurifier is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections. In cancer, the Hemopurifier is designed to deplete the presence of circulating tumor-derived exosomes that promote immune suppression, seed the spread of metastasis and inhibit the benefit of leading cancer therapies. The U.S. Food and Drug Administration, or FDA, has designated the Hemopurifier as a “Breakthrough Device” for two independent indications: · the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease; and · the treatment of life-threatening viruses that are not addressed with approved therapies. We believe the Hemopurifier can be a substantial advance in the treatment of patients with advanced and metastatic cancer through the clearance of exosomes that promote the growth and spread of tumors through multiple mechanisms. We are currently conducting a clinical trial in patients with advanced and metastatic head and neck cancer. We are initially focused on the treatment of solid tumors, including head and neck cancer, gastrointestinal cancers and other cancers. As we advance our clinical trials, we are in close contact with our clinical sites to navigate and assess the impact of the COVID-19 global pandemic on our clinical trials and current timelines. On October 4, 2019, the FDA approved our Investigational Device Exemption, or IDE, application to initiate an Early Feasibility Study, or EFS, of the Hemopurifier in patients with head and neck cancer in combination with standard of care pembrolizumab (Keytruda). The primary endpoint for the EFS, designed to enroll 10 to 12 subjects at a single center, is safety, with secondary endpoints including measures of exosome clearance and characterization, as well as response and survival rates. This study, initially being conducted at the UPMC Hillman Cancer Center in Pittsburgh, PA, or UPMC, has treated two patients to date. Due to lack of further patient enrollment, we and UPMC have terminated this study at UPMC. We are considering adding one or more alternative sites to this trial to accelerate recruitment. We also are in the process of designing other clinical trials in oncology. We also believe the Hemopurifier can be part of the broad-spectrum treatment of life-threatening highly glycosylated, or carbohydrate coated, viruses that are not addressed with an already approved treatment. In small-scale or early feasibility human studies, the Hemopurifier has been used in the past to treat individuals infected with human immunodeficiency virus, or HIV, hepatitis-C, and Ebola. Additionally, in vitro, On June 17, 2020, the FDA approved a supplement to our open IDE for the Hemopurifier in viral disease to allow for the testing of the Hemopurifier in patients with SARS-CoV-2/COVID-19 in a New Feasibility Study. That study is designed to enroll up to 40 subjects at up to 20 centers in the U.S. Subjects will have established laboratory diagnosis of COVID-19, be admitted to an intensive care unit, or ICU, and will have acute lung injury and/or severe or life-threatening disease, among other criteria. Endpoints for this study, in addition to safety, will include reduction in circulating virus as well as clinical outcomes (NCT # 04595903). Under Single Patient Emergency Use regulations, the Company has also treated two patients with COVID-19 with the Hemopurifier. We currently are experiencing a short-term disruption in our Hemopurifier supply, as our existing supply of Hemopurifiers expired on September 30, 2022. As previously disclosed, we are dependent on the FDA approval of qualified suppliers to manufacture our Hemopurifier. Our intended transition to a new supplier for Galanthus nivalis agglutinin, or GNA, is delayed as we work with the FDA for approval of our supplement to our Investigational Device Exemption, which is required to make this manufacturing change. We also obtained ethics review board approval and entered into a clinical trial agreement with Medanta Medicity Hospital, a multi-specialty hospital in Delhi NCR, India, for a COVID-19 clinical trial at that location. One patient has completed participation in the Indian COVID-19 study. The relevant authorities in India have accepted the use of the Hemopurifiers made with the GNA from our new supplier. Previously we were the majority owner of Exosome Sciences, Inc., or ESI, a company formed to focus on the discovery of exosomal biomarkers to diagnose and monitor life-threatening diseases, and thus consolidated ESI in our consolidated financial statements. For more than four years, the primary activities of ESI were limited to the payment of patent maintenance fees and applications. In September 2022, the Board of Directors of ESI and the Company, as the majority stockholder of ESI, approved the dissolution of ESI. Accordingly, ESI is eliminated from our September 30, 2022 balance sheet. Successful outcomes of human trials will also be required by the regulatory agencies of certain foreign countries where we plan to sell the Hemopurifier. Some of our patents may expire before FDA approval or approval in a foreign country, if any, is obtained. However, we believe that certain patent applications and/or other patents issued more recently will help protect the proprietary nature of the Hemopurifier treatment technology. In addition to the foregoing, we are monitoring closely the impact of the COVID-19 global pandemic, inflation, and the war in Ukraine on our business. Given the level of uncertainty regarding the duration and impact of these events on capital markets and the U.S. economy, we are unable to assess the impact on our timelines and future access to capital. The full extent to which the COVID-19 pandemic, inflation, and the war in Ukraine will impact our business, results of operations, financial condition, clinical trials, and preclinical research will depend on future developments, as well as the economic impact on national and international markets that are highly uncertain. Our executive offices are located at 11555 Sorrento Valley Road, Suite 203, San Diego, California 92121. Our telephone number is (619) 941-0360. Our website address is www.aethlonmedical.com. Our common stock is listed on the Nasdaq Capital Market under the symbol “AEMD.” SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES During the three months ended September 30, 2022, there were no changes to our significant accounting policies as described in our Annual Report on Form 10-K for the fiscal year ended March 31, 2022. Basis of Presentation and Use of Estimates The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP, for interim financial information and with the instructions to Form 10-Q and Article 8 of the Securities and Exchange Commission, or SEC, Regulation S-X. Accordingly, they should be read in conjunction with the audited financial statements and notes thereto for the fiscal year ended March 31, 2022, included in the Company’s Annual Report on Form 10-K filed with the SEC on June 28, 2022. The accompanying unaudited condensed consolidated financial statements include the accounts of Aethlon Medical, Inc. and its previously majority-owned subsidiary, ESI, which dissolved in September 2022. All significant inter-company transactions and balances have been eliminated in consolidation. The unaudited condensed consolidated financial statements contain all normal recurring accruals and adjustments that, in the opinion of management, are necessary to present fairly the condensed consolidated financial statements as of and for the six months ended September 30, 2022, and the condensed consolidated statement of cash flows for the six months ended September 30, 2022. Estimates were made relating to useful lives of fixed assets, impairment of assets, share-based compensation expense and accruals for clinical trial and research and development expenses. Actual results could differ materially from those estimates. The accompanying condensed consolidated balance sheet at March 31, 2022 has been derived from the audited consolidated balance sheet at March 31, 2022, contained in the above referenced 10-K. The results of operations for the six months ended September 30, 2022 are not necessarily indicative of the results to be expected for the full year or any future interim periods. Reclassifications Certain prior year balances within the unaudited condensed consolidated financial statements have been reclassified to conform to the current year presentation. LIQUIDITY AND GOING CONCERN Management expects existing cash as of September 30, 2022 to be sufficient to fund the Company’s operations for at least twelve months from the issuance date of these condensed consolidated financial statements. Restricted Cash To comply with the terms of our laboratory and office lease and our new lease for our manufacturing space, see Note 11, we caused our bank to issue two standby letters of credit, or the L/Cs, in the aggregate amount of $ 87,506

LOSS PER COMMON SHARE

LOSS PER COMMON SHARE	6 Months Ended
	Sep. 30, 2022
Earnings Per Share [Abstract]
LOSS PER COMMON SHARE	2. LOSS PER COMMON SHARE Basic loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period of computation. Diluted loss per share is computed similar to basic loss per share, except that the denominator is increased to include the number of additional dilutive common shares that would have been outstanding if potential common shares had been issued, if such additional common shares were dilutive. Since we had net losses for all periods presented, basic and diluted loss per share are the same, and additional potential common shares have been excluded, as their effect would be antidilutive. As of September 30, 2022 and 2021, an aggregate of 2,239,025 1,616,866

RESEARCH AND DEVELOPMENT EXPENS

RESEARCH AND DEVELOPMENT EXPENSES	6 Months Ended
	Sep. 30, 2022
Research and Development [Abstract]
RESEARCH AND DEVELOPMENT EXPENSES	3. RESEARCH AND DEVELOPMENT EXPENSES Our research and development costs are expensed as incurred. We incurred research and development expenses during the three and six month periods ended September 30, 2022 and 2021, which are included in various operating expense line items in the accompanying condensed consolidated statements of operations. Our research and development expenses in those periods were as follows: Research and Development expenses September 30, September 30, 2022 2021 Three months ended $ 852,464 $ 478,201 Six months ended $ 1,570,654 $ 1,045,539

RECENT ACCOUNTING PRONOUNCEMENT

RECENT ACCOUNTING PRONOUNCEMENTS	6 Months Ended
	Sep. 30, 2022
Accounting Changes and Error Corrections [Abstract]
RECENT ACCOUNTING PRONOUNCEMENTS	4. RECENT ACCOUNTING PRONOUNCEMENTS None.

EQUITY TRANSACTIONS IN THE SIX

EQUITY TRANSACTIONS IN THE SIX MONTHS ENDED SEPTEMBER 30, 2022	6 Months Ended
	Sep. 30, 2022
Equity [Abstract]
EQUITY TRANSACTIONS IN THE SIX MONTHS ENDED SEPTEMBER 30, 2022	5. EQUITY TRANSACTIONS IN THE SIX MONTHS ENDED SEPTEMBER 30, 2022 2022 At The Market Offering Agreement with H.C. Wainwright & Co., LLC On March 24, 2022, we entered into an At The Market Offering Agreement, or the 2022 ATM Agreement, with H.C. Wainwright & Co., LLC, or Wainwright, which established an at-the-market equity program pursuant to which we may offer and sell shares of our common stock from time to time as set forth in the 2022 ATM Agreement. The offering was registered under the Securities Act of 1933, as amended, or the Securities Act, pursuant to our shelf registration statement on S-3 (Registration Statement No. 333-259909), as previously filed with the SEC and declared effective on October 21, 2021. We filed a prospectus supplement, dated March 24, 2022, with the SEC that provides for the sale of shares of our common stock having an aggregate offering price of up to $15,000,000, or the 2022 ATM Shares. Under the 2022 ATM Agreement, Wainwright may sell the 2022 ATM Shares by any method permitted by law and deemed to be an “at the market offering” as defined in Rule 415 promulgated under the Securities Act, including sales made directly on the Nasdaq Capital Market, or on any other existing trading market for the 2022 ATM Shares. In addition, under the 2022 ATM Agreement, Wainwright may sell the 2022 ATM Shares in privately negotiated transactions with our consent and in block transactions. Under certain circumstances, we may instruct Wainwright not to sell the 2022 ATM Shares if the sales cannot be effected at or above the price designated by us from time to time. We are not obligated to make any sales of the 2022 ATM Shares under the 2022 ATM Agreement. The offering of the 2022 ATM Shares pursuant to the 2022 ATM Agreement will terminate upon the termination of the 2022 ATM Agreement by Wainwright or us, as permitted therein. The 2022 ATM Agreement contains customary representations, warranties and agreements by us, and customary indemnification and contribution rights and obligations of the parties. We agreed to pay Wainwright a placement fee of up to 3.0% of the aggregate gross proceeds from each sale of the 2022 ATM Shares. We also agreed to reimburse Wainwright for certain specified expenses in connection with entering into the 2022 ATM Agreement. In the six months ended September 30, 2022, we raised net proceeds of $ 8,927,211 229,610 27,153 7,480,836 1.19 Restricted Stock Unit Grants The Compensation Committee of the Board of Directors of the Company approved, effective as of April 1, 2022, pursuant to the terms of the Company’s Amended and Restated Non-Employee Directors Compensation Policy, or the Directors Compensation Policy, the grant of the annual Restricted Stock Unit awards, or RSUs, to each of the two non-employee directors of the Company then serving on the Board of Directors of the Company, or Board, and the grant of an RSU for the then newly appointed director. The RSU grants were made subject to stockholder approval of an increase of 1,800,000 50,000 75,000 1.46 34,247 51,370

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	6 Months Ended
	Sep. 30, 2022
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	6. RELATED PARTY TRANSACTIONS During the three months ended September 30, 2022, we accrued unpaid fees of $ 57,000 Due to related parties September 30, March 31, Accrued Board fees $ 57,000 $ 55,750 Accrued vacation to all employees 120,527 99,992 Total due to related parties $ 177,527 $ 155,742

OTHER CURRENT LIABILITIES

OTHER CURRENT LIABILITIES	6 Months Ended
	Sep. 30, 2022
Other Liabilities Disclosure [Abstract]
OTHER CURRENT LIABILITIES	7. OTHER CURRENT LIABILITIES Other current liabilities were comprised of the following items: Other Current Liabilities September 30, March 31, 2022 2022 Accrued professional fees $ 741,529 $ 696,893 Total other current liabilities $ 741,529 $ 696,893

STOCK COMPENSATION

STOCK COMPENSATION	6 Months Ended
	Sep. 30, 2022
Equity [Abstract]
STOCK COMPENSATION	8. STOCK COMPENSATION The following tables summarize share-based compensation expenses relating to RSUs and stock options and the effect on basic and diluted loss per common share during the three and six month periods ended September 30, 2022 and 2021: Share-based compensation expense relating to RSUs Three Months Ended September 30, 2022 Three Months Ended September 30, 2021 Six Months Ended Six Months Ended Vesting of stock options and restricted stock units $ 313,538 $ 201,062 $ 528,975 $ 321,216 Total stock-based compensation expense $ 313,538 $ 201,062 $ 528,975 $ 321,216 Weighted average number of common shares outstanding – basic and diluted 20,744,999 15,386,486 18,130,177 14,114,639 Basic and diluted loss per common share attributable to stock-based compensation expense $ (0.02 ) $ (0.01 ) $ (0.03 ) $ (0.02 ) All of the stock-based compensation expense recorded during the six months ended September 30, 2022 and 2021, an aggregate of $ 528,975 321,216 We review share-based compensation on a quarterly basis for changes to the estimate of expected award forfeitures based on actual forfeiture experience. The cumulative effect of adjusting the forfeiture rate for all expense amortization is recognized in the period the forfeiture estimate is changed. The effect of forfeiture adjustments for the six months ended September 30, 2022 was insignificant. Stock Option Activity During the six months ended September 30, 2022, we recognized a stock option grant made in the fiscal year ended March 31, 2022 to purchase 61,600 1,800,000 During the six months ended September 30, 2021, we issued a stock option grant to Charles J. Fisher, Jr., MD, our Chief Executive Officer, or CEO, for the purchase of 266,888 5.17 Stock options outstanding that have vested as of September 30, 2022 and stock options that are expected to vest subsequent to September 30, 2022 are as follows: Options outstanding that have vested and are expected to vest Number of Weighted Weighted Vested 440,206 $ 2.86 8.06 Expected to vest 1,271,327 $ 2.06 8.44 Total 1,711,533 A summary of stock option activity during the six months ended September 30, 2022 is presented below: Schedule of stock option activity Amount Range of Weighted Stock options outstanding at March 31, 2022 1,665,948 $ 1.28 - 142.50 $ 2.31 Exercised – $ – $ – Granted 61,600 $ 1.21 $ 1.21 Cancelled/Expired (16,015 ) $ 1.41 - 57 $ 3.54 Stock options outstanding at September 30, 2022 1,711,533 $ 1.28 - 142.50 $ 2.26 Stock options exercisable at September 30, 2022 440,206 $ 1.28 - 142.50 $ 2.86 On September 30, 2022, our outstanding stock options had no intrinsic value since the closing share price on that date of $ 0.58 At September 30, 2022, there was approximately $ 2,422,000 2.72

WARRANTS

WARRANTS	6 Months Ended
	Sep. 30, 2022
Warrants
WARRANTS	9. WARRANTS During the six months ended September 30, 2022 and 2021, we did not issue any warrants. A summary of warrant activity during the six months ended September 30, 2022 is presented below: Schedule of Warrant Activity Amount Range of Weighted Warrants outstanding at March 31, 2022 576,738 $ 1.50 – 59.25 $ 11.21 Exercised – $ – $ – Cancelled/Expired (49,246 ) $ 20.63 – 59.25 $ 50.69 Warrants outstanding at September 30, 2022 527,492 $ 1.50 – 16.50 $ 7.52 Warrants exercisable at September 30, 2022 527,492 $ 1.50 – 16.50 $ 7.52

GOVERNMENT CONTRACTS AND RELATE

GOVERNMENT CONTRACTS AND RELATED REVENUE RECOGNITION	6 Months Ended
	Sep. 30, 2022
Revenue from Contract with Customer [Abstract]
GOVERNMENT CONTRACTS AND RELATED REVENUE RECOGNITION	10. GOVERNMENT CONTRACTS AND RELATED REVENUE RECOGNITION We entered into the following contract with the National Cancer Institute, or NCI, part of the National Institutes of Health, or NIH, in September 2019: Phase 2 Melanoma Cancer Contract On September 12, 2019, the NCI awarded to us an SBIR Phase II Award Contract, for NIH/NCI Topic 359, entitled “A Device Prototype for Isolation of Melanoma Exosomes for Diagnostics and Treatment Monitoring”, or the Award Contract. The Award Contract amount is $ 1,860,561 The work performed pursuant to this Award Contract was focused on melanoma exosomes. This work followed from our completion of a Phase I contract for the Topic 359 solicitation that ran from September 2017 through June 2018, as described below. Following on the Phase I work, the deliverables in the Phase II program involved the design and testing of a pre-commercial prototype of a more advanced version of the exosome isolation platform. We did not record government contract revenue on the Phase 2 Melanoma Cancer Contract in the three and six month periods ended September 30, 2022. We recorded $ 114,849 229,698 The contract ended on September 15, 2022 and we presented the required final report to the NCI. Once the NCI completes the close out review of the contract, we expect to recognize as revenue the $ 574,245 Subaward with University of Pittsburgh In December 2020, we entered into a cost reimbursable subaward arrangement with the University of Pittsburgh in connection with an NIH contract entitled “Depleting Exosomes to Improve Responses to Immune Therapy in HNNCC.” Our share of the award was $ 256,750 17,117 34,234 In October 2022, we agreed with the University of Pittsburgh to terminate the subaward arrangement, effective as of November 10, 2022, since it related to our clinical trial in head and neck cancer in which the University of Pittsburgh was unable to recruit patients.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	6 Months Ended
	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	11. COMMITMENTS AND CONTINGENCIES CONTRACTUAL OBLIGATIONS AND COMMITMENTS On September 29, 2021, we entered into an agreement with a leading global contract research organization, or CRO, to oversee our clinical studies investigating the Hemopurifier, or the CRO Agreement. Pursuant to the CRO Agreement, the CRO agreed to manage our ongoing study of the Hemopurifier for patients who are critically ill with COVID-19 (NCT04595903), with the option for the parties to agree to include additional studies under the CRO Agreement. The CRO Agreement has a five year term, but may be extended by mutual agreement. The CRO Agreement also may be terminated by Aethlon without cause upon 30 days’ prior written notice and may be terminated by either party following notice for breach or insolvency of the other party. In November 2022, Aethlon provided the CRO with a 30-day termination notice due to the lack of enrollment of COVID patients and the delay in FDA approval of the Company’s GNA supplier for the manufacture of the Hemopurifiers. LEASE COMMITMENTS Previous Office and Lab Leases In September 2021, our lease of approximately 2,600 square feet of our previous executive office space at 9635 Granite Ridge Drive, Suite 100, San Diego, California 92123 expired. Through December 31, 2021, we rented approximately 1,700 square feet of laboratory space at 11585 Sorrento Valley Road, Suite 109, San Diego, California 92121, at the rate of $6,148 per month on a one-year lease that originally was to expire on November 30, 2020. In December 2020, we entered into a short-term lease extension running from December 1, 2020 through the completion date of our construction of our new laboratory space which is adjacent to our then current laboratory. New Office, Lab and Manufacturing Space Leases In December 2020, we entered into an agreement to lease approximately 2,823 square feet of office space and 1,807 square feet of laboratory space located at 11555 Sorrento Valley Road, Suite 203, San Diego, California 92121 and 11575 Sorrento Valley Road, Suite 200, San Diego, California 92121, respectively. The agreement carries a term of 63 months and we took possession of the office space effective October 1, 2021. We took possession of the lab space effective January 1, 2022. In October 2021, we entered into another lease for (i) approximately 22,260 square feet of space located at 11588 Sorrento Valley Road, San Diego, California 92121, or the Building, and (ii) 2,655 square feet of space located in the Building and commonly known as Suite 18 to house our manufacturing operations. The term is for 55 months and we took possession of the manufacturing space in August 2022. During the three months ended September 30, 2022, we recorded a $ 625,471 55 4.25 12,540 The office, lab and manufacturing leases are coterminous with a remaining term of 54 4.25 As of our September 30, 2022 balance sheet, we have a right-of-use lease asset of $ 1,282,328 In addition, the lease agreements for the new office, lab and manufacturing space required us to post a standby L/C in favor of the landlord in the aggregate amount of $ 87,506 46,726 40,780 87,506 Mobile Clean Room In addition, we rented a mobile clean room on a short term, month-to-month basis, where we housed our manufacturing operations until our permanent manufacturing space was completed. The mobile clean room was located on leased land near our office and lab and we paid $ 2,000 167,615 Overall, our rent expense, which is included in general and administrative expenses, approximated $ 309,000 167,000 LEGAL MATTERS From time to time, claims are made against us in the ordinary course of business, which could result in litigation. Claims and associated litigation are subject to inherent uncertainties and unfavorable outcomes could occur, such as monetary damages, fines, penalties or injunctions prohibiting us from selling one or more products or engaging in other activities. The occurrence of an unfavorable outcome in any specific period could have a material adverse effect on our results of operations for that period or future periods. We are not presently a party to any pending or threatened legal proceedings.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	6 Months Ended
	Sep. 30, 2022
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	12. SUBSEQUENT EVENTS Management has evaluated events subsequent to September 30, 2022 through the date that the accompanying condensed consolidated financial statements were filed with the SEC for transactions and other events which may require adjustment of and/or disclosure in such financial statements. On September 29, 2021, we entered into the CRO Agreement with the CRO to oversee our clinical studies investigating the Hemopurifier. Pursuant to the CRO Agreement, the CRO agreed to manage our ongoing study of the Hemopurifier for patients who are critically ill with COVID-19 (NCT04595903), with the option for the parties to agree to include additional studies under the CRO Agreement. The CRO Agreement has a five year term, but may be extended by mutual agreement. The CRO Agreement also may be terminated by Aethlon without cause upon 30 days’ prior written notice and may be terminated by either party following notice for breach or insolvency of the other party. In November 2022, Aethlon provided the CRO with a 30-day termination notice due to the lack of enrollment of COVID patients and the delay in FDA approval of the Company’s GNA supplier for the manufacture of the Hemopurifiers. In October 2022, we launched a wholly-owned subsidiary in Australia, formed to conduct clinical research in that country. Our current plan is that the subsidiary will initially focus on the oncology market in Australia.

NATURE OF BUSINESS AND BASIS _2

NATURE OF BUSINESS AND BASIS OF PRESENTATION ORGANIZATION (Policies)	6 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Basis of Presentation and Use of Estimates	Basis of Presentation and Use of Estimates The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP, for interim financial information and with the instructions to Form 10-Q and Article 8 of the Securities and Exchange Commission, or SEC, Regulation S-X. Accordingly, they should be read in conjunction with the audited financial statements and notes thereto for the fiscal year ended March 31, 2022, included in the Company’s Annual Report on Form 10-K filed with the SEC on June 28, 2022. The accompanying unaudited condensed consolidated financial statements include the accounts of Aethlon Medical, Inc. and its previously majority-owned subsidiary, ESI, which dissolved in September 2022. All significant inter-company transactions and balances have been eliminated in consolidation. The unaudited condensed consolidated financial statements contain all normal recurring accruals and adjustments that, in the opinion of management, are necessary to present fairly the condensed consolidated financial statements as of and for the six months ended September 30, 2022, and the condensed consolidated statement of cash flows for the six months ended September 30, 2022. Estimates were made relating to useful lives of fixed assets, impairment of assets, share-based compensation expense and accruals for clinical trial and research and development expenses. Actual results could differ materially from those estimates. The accompanying condensed consolidated balance sheet at March 31, 2022 has been derived from the audited consolidated balance sheet at March 31, 2022, contained in the above referenced 10-K. The results of operations for the six months ended September 30, 2022 are not necessarily indicative of the results to be expected for the full year or any future interim periods.
Reclassifications	Reclassifications Certain prior year balances within the unaudited condensed consolidated financial statements have been reclassified to conform to the current year presentation.
LIQUIDITY AND GOING CONCERN	LIQUIDITY AND GOING CONCERN Management expects existing cash as of September 30, 2022 to be sufficient to fund the Company’s operations for at least twelve months from the issuance date of these condensed consolidated financial statements.
Restricted Cash	Restricted Cash To comply with the terms of our laboratory and office lease and our new lease for our manufacturing space, see Note 11, we caused our bank to issue two standby letters of credit, or the L/Cs, in the aggregate amount of $ 87,506

RESEARCH AND DEVELOPMENT EXPE_2

RESEARCH AND DEVELOPMENT EXPENSES (Tables)	6 Months Ended
	Sep. 30, 2022
Research and Development [Abstract]
Research and Development expenses	Research and Development expenses September 30, September 30, 2022 2021 Three months ended $ 852,464 $ 478,201 Six months ended $ 1,570,654 $ 1,045,539

RELATED PARTY TRANSACTIONS (Tab

RELATED PARTY TRANSACTIONS (Tables)	6 Months Ended
	Sep. 30, 2022
Related Party Transactions [Abstract]
Due to related parties	Due to related parties September 30, March 31, Accrued Board fees $ 57,000 $ 55,750 Accrued vacation to all employees 120,527 99,992 Total due to related parties $ 177,527 $ 155,742

OTHER CURRENT LIABILITIES (Tabl

OTHER CURRENT LIABILITIES (Tables)	6 Months Ended
	Sep. 30, 2022
Other Liabilities Disclosure [Abstract]
Other Current Liabilities	Other Current Liabilities September 30, March 31, 2022 2022 Accrued professional fees $ 741,529 $ 696,893 Total other current liabilities $ 741,529 $ 696,893

STOCK COMPENSATION (Tables)

STOCK COMPENSATION (Tables)	6 Months Ended
	Sep. 30, 2022
Equity [Abstract]
Share-based compensation expense relating to RSUs	Share-based compensation expense relating to RSUs Three Months Ended September 30, 2022 Three Months Ended September 30, 2021 Six Months Ended Six Months Ended Vesting of stock options and restricted stock units $ 313,538 $ 201,062 $ 528,975 $ 321,216 Total stock-based compensation expense $ 313,538 $ 201,062 $ 528,975 $ 321,216 Weighted average number of common shares outstanding – basic and diluted 20,744,999 15,386,486 18,130,177 14,114,639 Basic and diluted loss per common share attributable to stock-based compensation expense $ (0.02 ) $ (0.01 ) $ (0.03 ) $ (0.02 )
Options outstanding that have vested and are expected to vest	Options outstanding that have vested and are expected to vest Number of Weighted Weighted Vested 440,206 $ 2.86 8.06 Expected to vest 1,271,327 $ 2.06 8.44 Total 1,711,533
Schedule of stock option activity	Schedule of stock option activity Amount Range of Weighted Stock options outstanding at March 31, 2022 1,665,948 $ 1.28 - 142.50 $ 2.31 Exercised – $ – $ – Granted 61,600 $ 1.21 $ 1.21 Cancelled/Expired (16,015 ) $ 1.41 - 57 $ 3.54 Stock options outstanding at September 30, 2022 1,711,533 $ 1.28 - 142.50 $ 2.26 Stock options exercisable at September 30, 2022 440,206 $ 1.28 - 142.50 $ 2.86

WARRANTS (Tables)

WARRANTS (Tables)	6 Months Ended
	Sep. 30, 2022
Warrants
Schedule of Warrant Activity	Schedule of Warrant Activity Amount Range of Weighted Warrants outstanding at March 31, 2022 576,738 $ 1.50 – 59.25 $ 11.21 Exercised – $ – $ – Cancelled/Expired (49,246 ) $ 20.63 – 59.25 $ 50.69 Warrants outstanding at September 30, 2022 527,492 $ 1.50 – 16.50 $ 7.52 Warrants exercisable at September 30, 2022 527,492 $ 1.50 – 16.50 $ 7.52

NATURE OF BUSINESS AND BASIS _3

NATURE OF BUSINESS AND BASIS OF PRESENTATION ORGANIZATION (Details Narrative)	Sep. 30, 2022 USD ($)
Restricted Cash [Member]
Security deposit	$ 87,506

LOSS PER COMMON SHARE (Details

LOSS PER COMMON SHARE (Details Narrative) - shares	6 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Earnings Per Share [Abstract]
Antidilutive shares	2,239,025	1,616,866

RESEARCH AND DEVELOPMENT EXPE_3

RESEARCH AND DEVELOPMENT EXPENSES (Details) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Research and Development [Abstract]
Research and development expense	$ 852,464	$ 478,201	$ 1,570,654	$ 1,045,539

EQUITY TRANSACTIONS IN THE SI_2

EQUITY TRANSACTIONS IN THE SIX MONTHS ENDED SEPTEMBER 30, 2022 (Details Narrative)	6 Months Ended
	Sep. 30, 2022 USD ($) $ / shares shares
Restricted Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Number of stock options granted	$ 50,000
Share price | $ / shares	$ 1.46
Restricted Stock [Member] | Director [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares grant | shares	51,370
Share-Based Payment Arrangement, Nonemployee [Member]
Subsidiary, Sale of Stock [Line Items]
Number of stock options granted	$ 75,000
Plan 2022 [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares authorized | shares	1,800,000
Plan 2020 [Member] | Restricted Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares grant | shares	34,247
Offering Agreement [Member]
Subsidiary, Sale of Stock [Line Items]
Proceeds from issuance of equity	$ 8,927,211
Stock issued new, shares issued | shares	7,480,836
Stock sale - average price per share | $ / shares	$ 1.19
Offering Agreement [Member] | Hc Wainwright [Member]
Subsidiary, Sale of Stock [Line Items]
Payment of commissions	$ 229,610
Offering Agreement [Member] | Other Offering Expense [Member]
Subsidiary, Sale of Stock [Line Items]
Payment of stock issuance costs	$ 27,153

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details) - USD ($)	Sep. 30, 2022	Mar. 31, 2022
Related Party Transaction [Line Items]
Due to related parties	$ 177,527	$ 155,742
Accrued Board Fees [Member]
Related Party Transaction [Line Items]
Due to related parties	57,000	55,750
Accrued Vacation [Member]
Related Party Transaction [Line Items]
Due to related parties	$ 120,527	$ 99,992

RELATED PARTY TRANSACTIONS (D_2

RELATED PARTY TRANSACTIONS (Details Narrative)	Sep. 30, 2022 USD ($)
Related Party Transactions [Abstract]
Accrued director fees	$ 57,000

OTHER CURRENT LIABILITIES (Deta

OTHER CURRENT LIABILITIES (Details) - USD ($)	Sep. 30, 2022	Mar. 31, 2022
Other Liabilities Disclosure [Abstract]
Accrued professional fees	$ 741,529	$ 696,893
Total other current liabilities	$ 741,529	$ 696,893

STOCK COMPENSATION (Details - S

STOCK COMPENSATION (Details - Stock compensation) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Interim Period, Costs Not Allocable [Line Items]
Total stock-based compensation expense	$ 313,538	$ 201,062	$ 528,975	$ 321,216
Weighted average number of common shares outstanding- basic and diluted	20,744,999	15,386,486	18,130,177	14,114,639
Basic and diluted loss per common share attributable to stock-based compensation expense	$ (0.02)	$ (0.01)	$ (0.03)	$ (0.02)
Vesting Options [Member]
Interim Period, Costs Not Allocable [Line Items]
Total stock-based compensation expense	$ 313,538	$ 201,062	$ 528,975	$ 321,216

STOCK COMPENSATION (Details - O

STOCK COMPENSATION (Details - Options vested and expected to vest) - Equity Option [Member]	6 Months Ended
	Sep. 30, 2022 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Options vested	440,206
Weighted average exercise price options vested | $ / shares	$ 2.86
Weighted average remaining contractual term options vested	8 years 21 days
Options expected to vest	1,271,327
Weighted average exercise price options expected to vest | $ / shares	$ 2.06
Weighted average remaining contractual term options expected to vest	8 years 5 months 8 days
Total options outstanding	1,711,533

STOCK COMPENSATION (Details -_2

STOCK COMPENSATION (Details - Option activity) - Options Held [Member]	6 Months Ended
	Sep. 30, 2022 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock options Outstanding, beginning balance | shares	1,665,948
Range of exercise prices, Option beginning	1.28 - 142.50
Outstanding, Weighted Average Exercise Price, beginning price | $ / shares	$ 2.31
Stock options exercised | shares	0
Exercised, Weighted Average Exercise Price | $ / shares	$ 0
Stock options granted | shares	61,600
Range of exercise prices, Option Granted	1.21
Granted, Weighted Average Exercise Price | $ / shares	$ 1.21
Stock options cancelled/forfeited | shares	(16,015)
Range of exercise prices, Option cancelled/expired	1.41 - 57
Cancelled/Forfeited, Weighted Average Exercise Price | $ / shares	$ 3.54
Stock options outstanding, ending balance | shares	1,711,533
Range of exercise prices, Option ending	1.28 - 142.50
Outstanding Weighted Average Exercise Price, ending price | $ / shares	$ 2.26
Stock options exercisable | shares	440,206
Range of exercise prices, Option exercisable	1.28 - 142.50
Exercisable, Weighted Average Exercise Price | $ / shares	$ 2.86

STOCK COMPENSATION (Details Nar

STOCK COMPENSATION (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock based compensation	$ 313,538	$ 201,062	$ 528,975	$ 321,216
Unrecognized compensation costs	$ 2,422,000		$ 2,422,000
Unrecognized compensation cost amortization period			2 years 8 months 19 days
Options Held [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Purchase price			$ 1.21
Share price	$ 0.58		$ 0.58
Equity 2020 Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Options granted			61,600
Number of shares authorized	1,800,000		1,800,000
Equity 2020 Plan [Member] | C E O [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Options granted			266,888
Purchase price			$ 5.17

WARRANTS (Details)

WARRANTS (Details) - Warrant [Member]	6 Months Ended
	Sep. 30, 2022 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Warrants Outstanding, Beginning | shares	576,738
Range of Exercise Price Outstanding, Beginning	1.50 – 59.25
Weighted Average Exercise Price Outstanding, Beginning | $ / shares	$ 11.21
Number of Warrants Exercised | shares	0
Weighted Average Exercise Price, Exercised | $ / shares	$ 0
Number of Warrants Cancelled/Expired | shares	(49,246)
Range of Exercise Price Cancelled Expired	20.63 – 59.25
Weighted Average Exercise Price Cancelled/Expired | $ / shares	$ 50.69
Number of Warrants Outstanding, Ending | shares	527,492
Range of Exercise Price Outstanding, Ending	1.50 – 16.50
Weighted Average Exercise Price Outstanding, Ending | $ / shares	$ 7.52
Number of Warrants Exercisable, Ending | shares	527,492
Range of Exercise Price Exercisable	1.50 – 16.50
Weighted Average Exercise Price Exercisable | $ / shares	$ 7.52

GOVERNMENT CONTRACTS AND RELA_2

GOVERNMENT CONTRACTS AND RELATED REVENUE RECOGNITION (Details Narrative) - USD ($)	3 Months Ended	6 Months Ended
	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Mar. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Deferred revenue		$ 574,245		$ 344,547
Melanoma Cancer Contract Phase 2 [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Award Contract amount		1,860,561
Contract revenue	$ 114,849		$ 229,698
Subaward With University Of Pittsburgh [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Award Contract amount		$ 256,750
Revenue	$ 17,117		$ 34,234

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)	6 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Mar. 31, 2022	Mar. 31, 2021
Right of use lease asset	$ 1,282,328		$ 696,698
Restricted cash	87,506	$ 46,726	87,506
Payment for rent per month	2,000
Rent expense	309,000	$ 167,000
Office Space [Member]
Right of use lease asset	625,471
Operating Lease, Liability	$ 625,471
Lease term	55 months
Borrowing rate	4.25%
Payments for rent	$ 12,540
Office Lab Space [Member]
Lease term	54 months
Borrowing rate	4.25%
New Office And Lab Space [Member]
Line of credit	$ 87,506			$ 46,726
Manufacturing Space [Member]
Line of credit			$ 40,780
Mobile Clean Room [Member]
Payments for rent	$ 167,615